Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study.

Fatih M. Uckun(University of Southern California), G H Reaman(Parker Hughes Cancer Center), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center), H N Sather, James B. Nachman(University of Chicago), ME Trigg(Parker Hughes Cancer Center), P S Gaynon(Children's Hospital of Los Angeles), Bruce Bostrom(Minnesota West Community & Technical College), Ray Hutchinson(University of Michigan), Martha G. Sensel(Parker Hughes Cancer Center)
Journal of Clinical Oncology
June 1, 1997
10.1200/jco.1997.15.6.2214
Cited by 106

Related Papers

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825
A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232
|Blood|2015|365
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
|Blood|2003|361